ストックスクリーナーアプリを入手
0.8843
0.63%
0.0053
前日終値:
$0.879
開ける：
$0.8646
24時間の取引高:
43,847
Relative Volume:
0.08
時価総額：
$37.17M
収益：
-
当期純損益:
$-31.37M
株価収益率:
-0.615
EPS:
-1.438
ネットキャッシュフロー:
$-4.23M
1週間 パフォーマンス:
+23.86%
1か月 パフォーマンス:
+15.83%
6か月 パフォーマンス:
-3.86%
1年 パフォーマンス:
-33.50%
1日の値動き範囲:
$0.8469
$0.899
1週間の範囲:
$0.7101
$0.90
52週間の値動き範囲:
$0.60
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.8845 | 32.52M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,170.00 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.36 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.22 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
151.71 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.09 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc (MIRA) 最新ニュース
Nearly 300 flights are cancelled due to problems in UK air traffic control system, flight monitor Flightradar24 reports - barchart.com
This Under-the-Radar Biopharma Is Moving MIRA-55, a Non-Opioid Pain Drug That Outperformed Morphine Closer to the Clinic - Barchart.com
Mira advances IND-enabling studies of MIRA-55 for pain - BioWorld News
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com South Africa
MIRA-55 toxicology results advance non-opioid pain program - TipRanks
MIRA Pharmaceuticals reports toxicology data for pain drug candidate - Investing.com
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND - GlobeNewswire
MIRA (MIRA) Update: Holds Near $0.73 on the Day; Key Range: $0.69 and $0.77 Define the Nearby Reference Levels for the Current SessionInitial Balance - vinanet.vn
MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest ReadingSegment Revenue Breakdown - vinanet.vn
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusBanking Earnings Report - vinanet.vn
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) Earnings Date and Reports 2026 - marketbeat.com
MIRA Pharmaceuticals Edges Higher: Stock Gains 1.37% as Shares Hold Key Support LevelWide Range Bar - dars.gov.et
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss of -$0.06 Per Share Highlights Cost DisciplineUpward Estimate Revision - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives 9.36% Stock GainSegment Revenue Breakdown - vinanet.vn
Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com South Africa
MIRA's obesity candidate shows rapid absorption in 7-day dog study - stocktitan.net
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 - Asianet Newsable
MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1 - TipRanks
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
12 Health Care Stocks Moving In Monday's After-Market SessionEnsysce Biosciences (NASDAQ:ENSC), TransC - Benzinga
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue Stage - vinanet.vn
MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA - TradingView
Tangible book value per share of MIRA Pharmaceuticals, Inc. – MUN:K6S - TradingView
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice - TipRanks
Mira advances MIRA-55 and SKNY-1 - bioworld.com
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies - GlobeNewswire
MIRA Pharmaceuticals completes toxicology studies for two candidates - Investing.com
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Stock DeclineEBITDA Margin Trends - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Q3 2025 Earnings: EPS Surprise of 26.47% on Narrowed Loss Despite No RevenueEarnings Miss Alert - vinanet.vn
MIRA|Mira Pharmaceuticals Inc|Price:0.764|Chg%:-0.025 - TradingKey
Mira Pharmaceuticals Inc (MIRA) Income Statement - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – DUS:K6S - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:+0.000 - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
MIRA Q3 2025 Earnings: Narrower-than-expected Loss Amid Pre-Revenue PhaseConsensus Miss Rate - vinanet.vn
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
Mira Pharmaceuticals Inc (MIRA) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.89%
大文字化:
|
ボリューム (24 時間):